A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+metastatic breast cancer

被引：0
|
作者：
Vukelja, S.
Rugo, H.
Vogel, C.
Borson, R.
Tan-Chiu, E.
Birkner, M.
Holden, S. N.
Klencke, B.
O'Shaughnessy, J.
Burris, H. A.
机构：
[1] Tyler Canc Ctr, Tyler, TX USA
[2] UCSF Comprehens Canc Ctr, San Francisco, CA USA
[3] Lynn Canc Inst, Boca Raton, FL USA
[4] St Louis Canc & Breast Inst, St Louis, MO USA
[5] Genentech Inc, San Francisco, CA 94080 USA
[6] Baylor Sammons Canc Ctr, Dallas, TX USA
[7] Sarah Cannon Canc, Nashville, TN USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：71S / 71S
页数：1
相关论文
共 50 条
  • [1] A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+metastatic breast cancer
    Krop, I. E.
    Beeram, M.
    Modi, S.
    Rabbee, N.
    Girish, S.
    Tibbitts, J.
    Holden, S. N.
    Lutzker, S. G.
    Burris, H. A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 219 - 219
  • [2] A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with advanced HER2+ breast cancer
    Krop, I. E.
    Beeram, M.
    Modi, S.
    Rabbee, N.
    Girish, S.
    Tibbitts, J.
    Holden, S. N.
    Lutzker, S. G.
    Burris, H. A.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S33 - S33
  • [3] A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+metastatic breast cancer (MBC): Final results
    Vogel, C. L.
    Burris, H. A.
    Limentani, S.
    Borson, R.
    O'Shaughnessy, J.
    Vukelja, S.
    Agresta, S.
    Klencke, B.
    Birkner, M.
    Rugo, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+metastatic breast cancer (BC)
    Beeram, M.
    Krop, I.
    Modi, S.
    Tolcher, A.
    Rabbee, N.
    Girish, S.
    Tibbitts, J.
    Holden, S.
    Lutzker, S.
    Burris, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+breast cancer (BC)
    Beeram, M.
    Burris, H. A., III
    Modi, S.
    Birkner, M.
    Girish, S.
    Tibbitts, J.
    Holden, S. N.
    Lutzker, S. G.
    Krop, I. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Trastuzumab-MCC-DM1 (TMAB-MCC-DM1), a first-in-class her2 antibody-drug conjugate (ADC) - A phase I study in patients (PTS) with Her2+metastatic breast cancer (BC)
    Beeram, M.
    Krop, I. E.
    Modi, S.
    Tolcher, A. W.
    Tibbitts, J.
    Rabbees, N.
    Girish, S.
    Lutzker, S. G.
    Holden, S. N.
    Burris, H. A.
    ANNALS OF ONCOLOGY, 2007, 18 : 21 - 21
  • [7] Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
    Krop, Ian E.
    Beeram, Muralidhar
    Modi, Shanu
    Jones, Suzanne F.
    Holden, Scott N.
    Yu, Wei
    Girish, Sandhya
    Tibbitts, Jay
    Yi, Joo-Hee
    Sliwkowski, Mark X.
    Jacobson, Fred
    Lutzker, Stuart G.
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) : 2698 - 2704
  • [8] A phase I study of a first-in-class HER2 antibody-drug conjugate in patients with HER2-overexpressing metastatic breast cancer.
    Burris, H. A.
    Krop, I. E.
    Modi, S.
    Rodon, J.
    Lutzker, S. G.
    Holden, S. N.
    Bhattacharya, S.
    Sliwkowski, M. X.
    Beeram, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S104 - S104
  • [9] A PHASE 2 STUDY OF THE HER2 ANTIBODY-DRUG CONJUGATE TRASTUZUMAB-DM1 (T-DM1) IN PATIENTS (PTS) WITH HER2-POSITIVE METASTATIC BREAST CANCER (MBC) PREVIOUSLY TREATED WITH TRASTUZUMAB, LAPATINIB, AND CHEMOTHERAPY
    Krop, I.
    LoRusso, P.
    Miller, K. D.
    Modi, S.
    Yardley, D.
    Rodriguez, G.
    Lu, M.
    Burington, B.
    Agresta, S.
    Rugo, H.
    ANNALS OF ONCOLOGY, 2010, 21 : 97 - 97
  • [10] Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+metastatic breast cancer
    Niculescu-Duvaz, Ion
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2010, 12 (03) : 350 - 360
12345